SCHEMBL24497376

SCHEMBL24497376

C=Cc1cc(S(=O)(=O)N(C)Cc2ccc(OC)cc2)cnc1Nc1ccc(C(F)(F)F)cn1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.42
▸ NPSR1 Q6W5P4 2/20 0.42
▸ CCR6 P51684 1/20 0.40
▸ BMP1 P13497 2/20 0.40
▸ MMP1 P03956 2/20 0.39
▸ MMP9 P14780 2/20 0.39
▸ MMP13 P45452 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ MDM2 Q00987 1/20 0.38
▸ LMNA P02545 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ LIPE Q05469 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ NR1H3 Q13133 1/20 0.35
▸ NAMPT P43490 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29648360 1.00 MAPT (0.42) MAPTNPSR1CCR6BMP1MMP1
SCHEMBL24497406 0.90 BMP1 (0.43) MAPTNPSR1BMP1MMP1MMP9
SCHEMBL24497405 0.88 MAPT (0.44) MAPTNPSR1CCR6BMP1MMP1
SCHEMBL29648375 0.88 MAPT (0.44) MAPTNPSR1CCR6BMP1MMP1
SCHEMBL24497371 0.87 BMP1 (0.44) MAPTNPSR1CCR6BMP1MMP1
SCHEMBL29648392 0.87 BMP1 (0.44) MAPTNPSR1CCR6BMP1MMP1
SCHEMBL30114634 0.81 BMP1 (0.50) MAPTNPSR1CCR6BMP1MMP1
SCHEMBL22718099 0.78 BMP1 (0.46) MAPTNPSR1CCR6BMP1MMP1
SCHEMBL24497432 0.77 MAPT (0.53) MAPTKDM4EMEN1KMT2AGAA
SCHEMBL29648339 0.77 MAPT (0.53) MAPTKDM4EMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4281073-A1 COMBINATION OF A 3-(IMIDAZOL-4-YL)-4-(AMINO)-BENZENESULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER Ikena Oncology, Inc. (US) 2023-11-29 — — EP disclosed
WO-2022120355-A1 TEAD DEGRADERS AND USES THEREOF Ikena Oncology, Inc. (US) 2022-06-09 — — WO disclosed
WO-2022120354-A1 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2022-06-09 — — WO disclosed
Send feedback